Jump to content

Lufotrelvir

From Wikipedia, the free encyclopedia
Lufotrelvir
Legal status
Legal status
  • US:Investigational drug
Identifiers
  • [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid
CAS Number
PubChemCID
DrugBank
UNII
KEGG
ChEBI
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC24H33N4O9P
Molar mass552.521g·mol−1
3D model (JSmol)
  • CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC
  • InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1
  • Key:FQKALOFOWPDTED-WBAXXEDZSA-N

Lufotrelvir(PF-07304814) is anantiviraldrug developed byPfizerwhich acts as a3CLprotease inhibitor.[1]It is aprodrugwith thephosphategroup being cleavedin vivoto yield the active agentPF-00835231.[2]Lufotrelvir is in humanclinical trialsfor the treatment ofCOVID-19,and shows good activity against COVID-19 including severalvariant strains,but unlike the related drugnirmatrelvirit is not orally active and must be administered byintravenous infusion,and so has been the less favoured candidate for clinical development overall.[3][4][5]

See also

[edit]

References

[edit]
  1. ^Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. (November 2020)."Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19".Journal of Medicinal Chemistry.63(21): 12725–12747.doi:10.1021/acs.jmedchem.0c01063.PMC7571312.PMID33054210.
  2. ^Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, et al. (October 2021)."Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19".Nature Communications.12(1): 6055.Bibcode:2021NatCo..12.6055B.doi:10.1038/s41467-021-26239-2.PMC8523698.PMID34663813.
  3. ^de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, et al. (March 2021)."A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLproinhibitor PF-00835231 as a potential new treatment for COVID-19 ".Journal of Virology.95(7).doi:10.1128/JVI.01819-20.PMC8139662.PMID33622961.
  4. ^Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ (March 2021)."Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study".Molecules.26(6): 1678.doi:10.3390/molecules26061678.PMC8002701.PMID33802860.
  5. ^Vandyck K, Deval J (August 2021)."Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection".Current Opinion in Virology.49:36–40.doi:10.1016/j.coviro.2021.04.006.PMC8075814.PMID34029993.